181 related articles for article (PubMed ID: 38196202)
21. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
[TBL] [Abstract][Full Text] [Related]
22. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
[TBL] [Abstract][Full Text] [Related]
23. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
24. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Bouleftour W; Sargos P; Magne N
Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
[TBL] [Abstract][Full Text] [Related]
25. Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
Mayer M; Nachtsheim L; Prinz J; Shabli S; Suchan M; Klußmann JP; Quaas A; Arolt C; Wolber P
Clin Exp Metastasis; 2023 Oct; 40(5):395-405. PubMed ID: 37480387
[TBL] [Abstract][Full Text] [Related]
26. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
[TBL] [Abstract][Full Text] [Related]
27. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
28. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
[TBL] [Abstract][Full Text] [Related]
29. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
30. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
Ueki H; Hinata N; Kitagawa K; Hara T; Terakawa T; Furukawa J; Harada K; Nakano Y; Komatsu M; Fujisawa M; Shirakawa T
Clin Transl Oncol; 2022 Mar; 24(3):568-577. PubMed ID: 34687441
[TBL] [Abstract][Full Text] [Related]
31. DNA demethylation and tri-methylation of H3K4 at the TACSTD2 promoter are complementary players for TROP2 regulation in colorectal cancer cells.
Gehring A; Huebner K; Rani H; Erlenbach-Wuensch K; Merkel S; Mahadevan V; Grutzmann R; Hartmann A; Schneider-Stock R
Sci Rep; 2024 Feb; 14(1):2683. PubMed ID: 38302503
[TBL] [Abstract][Full Text] [Related]
32. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
33. Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies.
Evmorfopoulos K; Mitrakas L; Karathanasis A; Zachos I; Tzortzis V; Vlachostergios PJ
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509415
[TBL] [Abstract][Full Text] [Related]
34. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
35. TACSTD2 upregulation is an early reaction to lung infection.
Lenárt S; Lenárt P; Knopfová L; Kotasová H; Pelková V; Sedláková V; Vacek O; Pokludová J; Čan V; Šmarda J; Souček K; Hampl A; Beneš P
Sci Rep; 2022 Jun; 12(1):9583. PubMed ID: 35688908
[TBL] [Abstract][Full Text] [Related]
36. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
38. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
[TBL] [Abstract][Full Text] [Related]
39. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Filippi L; Schillaci O
Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
[TBL] [Abstract][Full Text] [Related]
40. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]